Investment
Features
FeesSafety
Academy
More
Pluang+

Altrova Health settles C$215K debt by issuing shares, preserving cash and reducing liabilities.

Company Fundamentals
29 Sep 2026
Newsfile Corp
View Source
Bullish
Altrova Health settles C$215K debt by issuing shares, preserving cash and reducing liabilities.

Altrova Health Inc. has settled C$215,000 of outstanding debt by issuing 3,583,333 common shares at a price of C$0.06 per share to three creditors. This debt settlement did not bring in cash but helped reduce the company's liabilities and preserve cash for working capital. The issued shares are subject to a hold period of four months and one day. This move supports Altrova Health's strategy to manage its financial position while continuing to build its health solutions portfolio.

Altrova Health's recent debt settlement is presented here alongside Pluang's health sector market snapshot as of Sep 30, 2026 02:41 WIB. Of 100 health-sector US stocks priced on Pluang, 35 advanced while 65 declined today. Notable movers include Heron Therapeutics Inc (HRTX) at USD 0.31 with a 6.55% gain and Summit Therapeutics Inc (SMMT) at USD 16.46 rising 6.33%.

More News

Micron projects record $51.33B revenue driven by AI memory demand, with EPS soaring to $31.72 this quarter.

Micron projects record $51.33B revenue driven by AI memory demand, with EPS soaring to $31.72 this quarter.

Micron Technology is set to report record quarterly revenue of up to $51.33 billion, fueled by strong demand for high-bandwidth memory in the AI market. Earnings per share are expected to jump significantly to around $31.72, compared to $3.03 last ye...

Company Fundamentals
Bullish
1 hour ago
Sangoma beats EPS estimates but misses revenue; acquisition deal boosts shares 35%.

Sangoma beats EPS estimates but misses revenue; acquisition deal boosts shares 35%.

Sangoma Technologies reported a smaller-than-expected loss with an EPS of -$0.08, beating analyst estimates of -$2.19, though its revenue of $48.55 million slightly missed expectations. Despite ongoing profitability challenges reflected in a negative...

Company Fundamentals
Bullish
3 hours ago
Iovance Biotherapeutics raises 2026 revenue forecast with strong Q2 sales and analyst optimism.

Iovance Biotherapeutics raises 2026 revenue forecast with strong Q2 sales and analyst optimism.

Iovance Biotherapeutics has increased its full-year 2026 revenue guidance to $410-$420 million, reflecting nearly 60% growth driven by strong U.S. demand for its cancer therapy Amtagvi, which generated $91 million in Q2 sales. Analyst Joseph Pantgini...

Analyst Insights
Bullish
3 hours ago
uniQure shares drop 37% after mixed results in Huntington's gene therapy trial

uniQure shares drop 37% after mixed results in Huntington's gene therapy trial

uniQure's stock fell sharply by 37% following a four-year update on its AMT-130 gene therapy for Huntington's disease, which showed reduced effectiveness from 80% at three years to 44% at four years, failing to reach statistical significance. Despite...

Market News
Bearish
4 hours ago
Hybrid Power Solutions Q4 revenue soars 707% YoY with narrowing net loss, eyes defence sector growth.

Hybrid Power Solutions Q4 revenue soars 707% YoY with narrowing net loss, eyes defence sector growth.

Hybrid Power Solutions reported a 707% year-over-year revenue increase to $886,333 in Q4 fiscal 2026, driven by higher sales volumes of its clean power systems. The company narrowed its quarterly net loss by 52% compared to the previous quarter, refl...

Company Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App